Effects of actin filaments of fibrin clot structure and lysis
AssigneeBiogen, Inc.
InventorsPaul A. Janmey, Jennifer A. Lamb, Stuart E. Lind, Thomas P. Stossel
Life of this patent
Estimating the term…
Abstract
The present invention relates to therapeutic methods wherein an actin-binding protein, preferably gelsolin or DBP, is administered to a patient with actin-containing clots in order to remove actin from the clots. The invention also relates to diagnostic methods in which actin is removed from an actin-containing clot in vitro and quantitated.
Claims16
A method for eluting and quantitating the actin in an actin-containing clot, comprising the steps of (1) removing plasma from a subject with tissue injury, (2) allowing said plasma to form a clot in vitro, (3) isolating said clot formed in step (2), (4) incubating said clot in liquid medium with at least one actin-binding protein, and (5) quantitating the amount of actin in said medium.
A method for reducing the amount of actin in an actin-containing clot in a subject comprising the step of infusing an efficacious level of at least one actin-binding protein into said subject with said actin-containing clot.
A method for restoring the normal viscoelastic properties and susceptibility to plasmin-mediated lysis to a fibrin clot formed in a subject after tissue injury, comprising the step of administering an efficacious level of at least one actin-binding protein to a subject with an actin-containing clot.
Dependencies are inferred from the claim text.